BCG, a live attenuated Mycobacterium bovis strain, represents one of the most promising live vectors to deliver foreign antigens to the immune system. Indeed, BCG has been used in more than 3 billion people, with a very low incidence of serious side effects. Recently, the development of integrative and extrachromosomal expression vectors has enabled cloning and expression of foreign genes in BCG (2, 21, 24) . A variety of viral, bacterial and parasitic antigens have been now successfully expressed in BCG (2, 7, 11, 21, 23, 24) . In experimental models, recombinant BCG (rBCG) expressing foreign antigens was shown to elicit protective immunity against Lyme disease (20) , pneumococcal infection (14) , and cutaneous leishmaniasis (1, 4) . It has also been demonstrated that oral or intranasal immunization with rBCG induces substained systemic and mucosal specific immune responses (12, 13) .
Because of the high number of BCG-vaccinated people, we have recently analyzed the influence of BCG priming on immune responses induced by rBCG expressing a foreign antigen. Surprisingly, this study demonstrated that BCG priming induced a strong potentiation of the antibody response directed against a heterologous antigen delivered by rBCG (9) . Therefore, vaccination with BCG is not a limitation for the use of rBCG vaccines in humans but, in contrast, may even increase their potency.
Different clinical trials estimated BCG protection efficiency against tuberculosis to be from 0 to 80% (25) . Among the various factors interfering with the induction of immune responses, the genetic diversity of vaccinated populations could be responsible for these differences in the BCG protective effect. Indeed, it is now well established that innate resistance to mycobacterial infections in mice is under genetic control (18) . This genetic difference in immune responsiveness to BCG may also modulate the immune responses to future rBCG vaccines. It is therefore of major importance to determine if such genetic control could interfere with the immune responses induced against recombinant antigens expressed by rBCG.
To address this question, we examined the immune responses of various inbred strains of mice to rBCG expressing ␤-galactosidase. The present study demonstrated that there are strong differences in the capacities of different strains of mice to develop an antibody response against this antigen delivered by rBCG. The analysis of immune responses of Ity or H-2 congenic strains of mice revealed the complexity of the genetic control of these responses.
MATERIALS AND METHODS
Mice. Female BALB/c, C57BL/6, C3H/HeOuJ, and CBA mice, 6 to 8 weeks old, were obtained from Iffa Credo (l'Arbresle, France).
Female BALB/c, BALB/B, BALB/K, C57BL/10, B10.Br, and B10.D2 mice were obtained from Olac Ltd. These BALB/c mice have integrated through repetitive backcrosses a fragment of chromosome 1 from Salmonella-resistant strains DBA/2 and CBA, respectively. Both strains carry the resistance allele of the Ity gene. BALB/c mice from the Institut National de la Recherche Agronomique were used in experiments comparing the responses of C.D2, C.CB, and BALB/c mice.
Microorganisms. The M. bovis BCG strain Pasteur 1173P2 and the rBCG strain expressing lacZ under the promoter p AN from Mycobacterium paratuberculosis, rBCG(p AN lacZ) [previously named rBCG(lacZ) or rBCG(pAM320)], were previously described (9, 15, 24) . The rBCG strain expressing lacZ under the promoter pblaF*, rBCG(pblaF* lacZ), was constructed by operon fusion between the CII-lacZ reporter cassette of pJEM 15 and the promoter pblaF* from the Mycobacterium fortuitum ␤-lactamase gene, thus resulting in plasmid pJN30 (22) .
Higher levels of ␤-galactosidase activity were found in sonicated extracts of BCG expressing lacZ fused to pblaF* as compared to p AN (2,224 Ϯ 337 versus 364 Ϯ 48 U) (22) .
These three BCG strains were grown as surface veils on Sauton medium, and vaccine suspensions were prepared according to the classical procedure by grinding the bacillary mass on a steel ball mill as previously described (9, 10) . The vaccine suspensions were stored at Ϫ70°C until use. The number of CFU per milliliter was determined by plating suitable saline dilutions on Middlebrook 7H10 agar with or without kanamycin (10 g/ml) and X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactosidase) (1 g/ml) to check the stability of the plasmids in rBCG strains expressing ␤-galactosidase.
BCG growth in target organs. The growth of BCG strains was monitored by the enumeration of BCG and rBCG CFU in the spleens of immunized mice, as previously described (9) . At various intervals after immunization, the spleens of mice were homogenized (Stomacher Lab-Blender 80; Bioblock), and suitable dilutions were plated on Middlebrook 7H11 medium with or without kanamycin (10 g/ml) or X-Gal (1 g/ml) to determine the numbers of CFU of BCG and rBCG, respectively. The number of rBCG CFU was determined by counting the blue colonies on X-Gal plates.
Analysis of antibody responses. The mouse sera were tested for antibodies against ␤-galactosidase by enzyme-linked immunosorbent assay (ELISA) as previously described (9) . The 96-well microtiter trays (Nunc) were coated with 1 g of purified ␤-galactosidase (Boehringer, Mannheim, Germany) per well in phosphate-buffered saline (PBS) containing 0.1% Tween (1 h at 37°C and 16 h at 4°C). After three washes, sera diluted in buffer (PBS, 0.1% Tween 20, 1% bovine serum albumin) were added to the wells and left for 2 h at 37°C. After three washes, the wells were treated with goat anti-mouse immunoglobulin G-alkaline phosphatase conjugate (Caltag Laboratories, San Francisco, Calif.) for 1 h, and then 1 mg of p-nitrophenylphosphate per ml was added as the substrate. After 30 min of incubation at 37°C, the plates were read photometrically at 405 nm in a micro-ELISA Autoreader (Dynatech, Marnes la Coquette, France).
The negative control consisted of pooled normal BALB/c mouse sera. Individual titers were expressed as the log 10 of the highest dilution that gave an absorbance twice as high as that of the negative control. Titers (Ϯ standard errors) were calculated as the arithmetic mean of the log 10 titer.
Statistics. ELISA titers were compared by using the Mann-Whitney U test. A P value of Ն0.05 was considered nonsignificant.
Assay for IFN-␥. Cell suspensions were aseptically prepared by squeezing spleens between two sterile glass slides. Cells were cultured in RPMI 1640 (Seromed, Munich, Germany) supplemented with 10% fetal calf serum, 2 mM glutamine (Seromed), 50 M 2-mercaptoethanol, and antibiotics. A total of 4 ϫ 10 6 cells were incubated with medium alone or with 10 g of either ␤-galactosidase (Boehringer) or purified protein derivative (PPD) per ml in a 1-ml volume in flat-bottom 24-well plates (Nunc, Roskilde, Denmark). Supernatants were harvested at 96 h, and the level of gamma interferon (IFN-␥) was determined by sandwich ELISA with R4-6A2 (Pharmingen, San Diego, Calif.) as a capture antibody. Ninety-six-well microplates (Nunc) were coated with this monoclonal antibody (MAb) by overnight incubation at 4°C. The plates were then blocked with 1% bovine serum albumin (Boehringer) in PBS for 1 h at 37°C and were next incubated with supernatants for 1 h at 37°C, and then the secondary biotinylated anti-interferon-specific MAb (XMG2.2; Pharmingen) was added and left for 1 h at 37°C. The binding of the second MAb was detected with streptavidin-horseradish peroxidase (Amersham, Les Ulis, France). After three washes, the plates were developed by addition of o-phenylenediamine (Sigma) and hydrogen peroxide (Sigma). The reaction was stopped with sulfuric acid, and the plates were then read at 492 nm in an ELISA reader (Dynatech). All assays were standardized with recombinant murine IFN-␥ purchased from Pharmingen. Results were expressed in picograms per milliliter.
RESULTS

Comparison of the anti-␤-galactosidase antibody responses of various strains of mice immunized with rBCG(p AN lacZ).
We previously showed that BALB/c mice immunized with rBCG expressing ␤-galactosidase under the control of the p AN promoter developed good humoral and cellular immune responses directed against this antigen (15) . To evaluate the capacity of this rBCG strain to stimulate immune responses in various strains of mice, we therefore immunized BALB/c, C57BL/6, C3H, and CBA mice with rBCG(p AN lacZ) and analyzed their anti-␤-galactosidase antibody responses. As shown in Fig. 1 , BALB/c mice immunized with 5 ϫ 10 6 CFU of rBCG developed a significant antibody response against ␤-galactosidase which further increased following booster injections with 1 ϫ 10 6 CFU of rBCG at days 29 and 57. Following two injections with rBCG(p AN lacZ), C57BL/6, C3H, and CBA mice also developed specific anti-␤-galactosidase antibody responses. However, these responses remained low and at day 56 had returned to levels indistinguishable from those of non-BCG-immunized animals (data not shown). Following a third injection with rBCG(p AN lacZ), the antibody responses of these three strains of mice increased but remained 1 to 2 log units lower than the antibody response of BALB/c mice. Similar results were obtained after immunization of BALB/c and C57BL/6 mice with lower doses of this rBCG strain (5 ϫ 10 5 CFU at day 0, followed by 1 ϫ 10 5 CFU at days 29 and 57). This low immunogenicity in some strains of mice of this rBCG strain expressing ␤-galactosidase could be due to a more rapid elimination of this BCG strain in the lymphoid organs of these animals, leading to a lower stimulation of immune responses. We therefore compared the growth capacities of rBCG (p AN lacZ) in these strains of mice by enumeration of the CFU in the spleen after intravenous immunization. As shown in Fig.  2A , an increase in BCG CFU was observed 2 weeks after the injection of rBCG(p AN lacZ) in C57BL/6 and BALB/c mice, followed by a slow decrease at day 28. In contrast, in C3H mice, the number of CFU began to decrease 2 weeks after infection. Following booster injections, the number of CFU remained unchanged in BALB/c and C3H mice 4 months after injection, whereas it decreased rapidly in C57BL/6 mice and was significantly lower in this strain than in BALB/c and C3H mice.
Similar results were obtained when the recovery of rBCG in the spleen was analyzed (Fig. 2B ). These results show that the lower anti-␤-galactosidase response of C3H mice was not due to a faster elimination of rBCG in these mice. However, such a difference in the growth capacity of rBCG(p AN lacZ) can be responsible for the very low anti-␤-galactosidase antibody response of C57BL/6 mice.
We previously demonstrated that BCG-primed BALB/c mice developed high antibody responses against ␤-galactosidase expressed by rBCG(p AN lacZ), as compared with mice never exposed to BCG (9) . We therefore tested whether BCG priming could also affect the antibody response to rBCG(p AN lacZ) in strains of mice which respond poorly to this rBCG strain. BALB/c and C3H mice received an intravenous injection of 10 6 CFU of BCG 1 month before being immunized with rBCG(p AN lacZ). As shown in Fig. 3 , priming with BCG strongly enhanced the anti-␤-galactosidase antibody response of BALB/c mice, confirming our previous findings (9) . In contrast, the antibody response of C3H mice was only slightly affected by this priming with BCG. These results therefore demonstrated that there is a strong difference between the capacities of BALB/c and C3H mice to produce antibodies against ␤-galactosidase presented by rBCG, even under conditions leading to optimal immunogenicity of this antigen.
Comparison of the immunogenicities of purified ␤-galactosidase in various strains of mice. We previously demonstrated that antibody responses induced against an antigen delivered by recombinant attenuated Salmonella typhimurium is under genetic control (6). This genetic control was shown to be related to differences in responsiveness of different strains of mice to low doses of this antigen. We therefore analyzed if such differences in responsiveness to ␤-galactosidase exist between the strains of mice used in this study.
BALB/c, C57BL/6, and C3H mice were injected with various doses of ␤-galactosidase in the absence of adjuvant. As shown in Fig. 4 , C57BL/6 mice responded poorly to ␤-galactosidase in comparison to BALB/c and C3H mice, which developed high antibody responses even after being injected with 1 g of purified ␤-galactosidase. Similar differences in the antibody responses of C57BL/6, C3H, and BALB/c mice were observed after immunization with ␤-galactosidase mixed with alum (data not shown). These results therefore showed that differences in responsiveness to ␤-galactosidase cannot be responsible for the low response of C3H mice to rBCG(p AN lacZ) but can explain the poor immunogenicity of this rBCG strain in C57BL/6 mice. Increased expression of ␤-galactosidase by rBCG overcomes the low responsiveness of some strains of mice to rBCG expressing ␤-galactosidase. The results described above clearly demonstrated that some strains of mice, such as C57BL/6 mice, are low responders to ␤-galactosidase and may therefore require that rBCG deliver large amounts of antigen to mount a significant level of antibody response. To test this hypothesis, various strains of mice were immunized with rBCG expressing the lacZ gene under either the p AN or pblaF* promoter. It was previously shown that a higher level of ␤-galactosidase activity can be found in sonicated extracts of BCG expressing lacZ fused to pblaF* as compared to p AN (22) .
As shown in Fig. 5 , all strains of mice tested developed higher anti-␤-galactosidase antibody responses after immunization with rBCG(pblaF* lacZ) than after immunization with rBCG(p AN lacZ). Moreover, after three injections of rBCG (pblaF* lacZ), the four strains of mice tested developed antibody responses higher than 4 log 10 units. Increasing the level of ␤-galactosidase produced by rBCG therefore overcame the genetic unresponsiveness of some strains of mice to rBCG expressing ␤-galactosidase.
Genetic control of interferon production by spleen cells from mice immunized with rBCG. The previous results show that antibody responses to ␤-galactosidase delivered by rBCG are genetically controlled. To analyze if such genetic control could also affect T-cell responses, we then analyzed the capacities of three different strains of mice to produce IFN-␥ after rBCG immunization. As shown in Fig. 6 , a strong production of IFN-␥ was observed after PPD stimulation of spleen cells from BALB/c, C3H, and C57BL/6 mice immunized with wildtype BCG or rBCG, whereas normal mouse spleen cells did not respond to PPD (data not shown). After in vitro stimulation with ␤-galactosidase, significant levels of IFN-␥ production were also found in supernatants of spleen cells from BALB/ mice immunized with rBCG(p AN lacZ) (Fig. 6 ). This production was greater, however, in spleen cells from mice immunized with rBCG(pblaF* lacZ). Interestingly, C3H mice immunized with rBCG(p AN lacZ) or rBCG(pblaF* lacZ) produced very high levels of IFN-␥, in contrast to immunized C57BL/6 mice, which did not produce any significant amounts of this cytokine.
Influence of the Bcg gene on immune responses to ␤-galactosidase expressed by rBCG. The natural resistance of mice to BCG is controlled by a locus called Ity, Lsh, and Bcg, for S. typhimurium, Leishmania donovani, and M. bovis (16, 18, 19) . Therefore, to determine whether this gene could control the induction of humoral and cellular immune responses to an antigen expressed by rBCG, we have compared the anti-␤-galactosidase responses of Ity congenic strains of mice.
Three Ity congenic strains of mice were used: BALB/c (Ity s ), C.D2 Idh1 ) mice developed high antibody responses after immunization with rBCG(pblaF* lacZ), whereas, as previously observed, lower responses were obtained in mice immunized with rBCG(p AN lacZ). After immunization with rBCG(pblaF* lacZ), no difference between the responses of the three congenic strains of mice was found. Slightly higher anti-␤-galactosidase levels, however, were obtained in BALB/K mice immunized with rBCG(p AN lacZ) as compared to BALB/c and BALB/B mice. Similar results were obtained with H-2 congenic B10 strains of mice, which developed higher anti-␤-galactosidase antibody responses after immunization with rBCG(pblaF* lacZ) than after rBCG(p AN lacZ) injection (Fig. 9) . In both cases, significantly higher responses were observed in B10.Br (H-2 6 CFU of these various BCG strains. One month later, spleens were harvested and cell suspensions were stimulated in vitro with medium, ␤-galactosidase (10 g/ml), or PPD (10 g/ml). Supernatants were harvested 96 h later, and IFN-␥ levels were determined by ELISA. Results are expressed in picograms per milliliter and are given as means Ϯ standard errors for duplicate cultures.
netic background, may behave as low (C3H) or high (B10.Br) responders to ␤-galactosidase delivered by rBCG.
DISCUSSION
In the present study, we have analyzed the antibody responses of various inbred strains of mice immunized with rBCG expressing ␤-galactosidase under the control of two different promoters. After immunization with rBCG(p AN lacZ), a strong difference between the levels of anti-␤-galactosidase antibodies produced by these different strains of mice was observed. The low immunogenicity of rBCG(p AN lacZ) in some strains of mice could be related to a decreased BCG multiplication in the target organs in these mice. Indeed, multiplication of BCG in the reticuloendoethelial tissues of the mouse is controlled by the Bcg locus, which exists in two allelic forms, resistant (Bcg r ) and susceptible (Bcg S ) (18, 19) . After intravenous injection of small doses of BCG, the mean numbers of CFU recovered from the spleens of sensitive strains 4 weeks after infection were at least 10 times higher than those in resistant ones (8) . A rapid elimination of rBCG in the Bcg r C3H mice could explain the low antibody response of this mouse strain to ␤-galactosidase, by decreasing the amount of antigen delivered to lymphoid organs. However, whereas C57BL/6 and BALB/c mice are both Bcg S (8) , rBCG(p AN lacZ) induced good anti-␤-galactosidase levels in BALB/c mice but not in C57BL/6 mice. The analysis of BCG recovery in the spleens of these mice at various times after infection demonstrated that while rBCG grows better in both BALB/c and C57BL/6 mice than in C3H mice after a first injection, a more rapid elimination of rBCG can be demonstrated in C57BL/6 mice after two or three rBCG injections. Interestingly, although both C57BL/10 and BALB/c mice bear the susceptible phenotype of innate resistance, BCG vaccination was shown to generate efficient acquired protective immunity in C57BL/10 mice, but not in BALB/c mice (26) . This result could explain the difference observed in the present study between BCG elimination in BCG-immune BALB/c and C57BL/6 mice. Differences in T-cell responses induced by BCG in these two strains of mice were also recently demonstrated (5) .
To test directly the influence of the Bcg gene on the antibody responses to rBCG, we have used Ity congenic strains of mice. These experiments clearly demonstrated that there are no significant differences in the capacities of Ity s and Ity r congenic mice to produce anti-␤-galactosidase antibodies or to develop a T-cell response following immunization with rBCG(p AN lacZ).
In a previous study, we have observed that genetic factors modulate the immune responses to the MalE antigen delivered by recombinant attenuated S. typhimurium (6) . The major genetic influence was shown to be exerted by H-2 genes, which control the responsiveness of different strains of mice to low doses of MalE (6) . In the present study, we demonstrated that mouse strains differ also by their capacities to respond to low doses of ␤-galactosidase. The lack of response of C57BL/6 mice to limited amounts of ␤-galactosidase can therefore explain the low immunogenicity of rBCG(p AN lacZ) in this mouse strain, as compared to BALB/c or C3H mice, which produced good anti-␤-galactosidase responses even after immunization with low doses of this antigen. In agreement with this hypothesis, following immunization with rBCG(pblaF* lacZ), which produced approximately sixfold-larger amounts of ␤-galactosidase than rBCG(p AN lacZ) (22) , all strains of mice developed strong antibody responses. However, the anti-␤-galactosidase antibody responses of C57BL/6 and C57BL/10 mice remained significantly lower than that of BALB/c mice, showing that increasing the amount of foreign antigen delivered by rBCG does not totally overcome the genetic difference between these mouse strains.
To further analyze the mechanisms of this genetic control of responsiveness to rBCG, we have compared the antibody responses of H-2 congenic mice in two different backgrounds corresponding, in both cases, to Bcg S mice. These experiments clearly show that H-2 genes play a major role in the control of these responses. Indeed, whereas C57BL/10 (H-2 b ) and B10.D2 (H-2 d ) mice responded very poorly to rBCG(p AN lacZ), B10.Br (H-2 k ) mice developed antibody responses comparable to those of BALB/c mice. The antibody response of B10.Br mice to rBCG(pblaF* lacZ) was also significantly higher than those of C57BL/10 and B10.D2 mice. This effect could indeed be related to the observation that C3H mice responded well to low doses of ␤-galactosidase. Such an effect of H-2 k haplotype was also observed with H-2 congenic BALB/c mice, but only after immunization with rBCG(p AN lacZ). Together, these results indicate that H-2 genes play an important role in the induction of immune responses directed against antigens delivered by rBCG but that this effect can be evidenced only if the amount of antigen delivered to the immune system is suboptimal. This last hypothesis is in very good agreement with our recent findings that C57BL/6 mice developed very good antibody responses to the MalE antigen delivered by rBCG (data not shown). Indeed, this mouse strain is a high responder to MalE and responds to very low doses of this protein (6) .
These last findings can therefore explain the differences in responsiveness of BALB/c and C57BL/6 mice. However, since C3H mice also respond to low doses of ␤-galactosidase, they cannot account for the lack of responsiveness of this strain to rBCG(p AN lacZ). However, the analysis of interferon production in rBCG-immunized C3H mice clearly demonstrated that these mice developed a very strong ␤-galactosidase-specific T-cell response. The lack of induction of an antibody response in C3H mice by rBCG(p AN lacZ) may therefore reflect the induction in this strain of a strong CD4 ϩ immune response highly polarized towards a Th1 phenotype.
Together, the results of the present study demonstrated that the induction of immune responses against an antigen delivered by rBCG is under complex genetic influences. Some of these factors are certainly specific to the antigen expressed by the rBCG. Indeed, using rBCG expressing the outer surface protein A antigen of Borrelia burdorferi, Stover et al. (20) have obtained high antibody responses in C3H mice, whereas BALB/c mice required boosting to develop comparable responses. It is interesting that these two mouse strains immunized with rBCG vaccines expressing this antigen as a lipoprotein developed strong specific antibody responses (20) , which is in good agreement with our recent finding that increasing the level of expression of the heterologous antigen can, at least partially, overcome the unresponsiveness to rBCG. Other factors can be linked to genetic resistance to BCG itself, although in the present study, we failed to detect any influence of the Ity/Bcg gene on the immune response to rBCG. However, there is now substantial evidence that genetic factors are crucial elements in determining susceptibility to mycobacterial infections in humans (18) , and the human natural resistance-associated macrophage protein gene, a candidate gene for Bcg, has been recently cloned (3) . The influence of this gene on the human responses to antigens delivered by rBCG remains to be identified. Moreover, as shown in the present study, HLA genes controlling the response to the recombinant antigen itself could also play a major role in determining the levels of the immune responses induced against these recombinant microorganisms. The understanding of the mechanisms involved in the control of the immune responses directed against rBCG is therefore of crucial importance in the development of new live recombinant vaccines based on M. bovis BCG.
